

Main Office: Loc. Bellaria, 35 - 53018 Sovicille (SI), Italy
Tel. (+39) 0577 17816
Administration Fax (+39) 0577 1781680
Clinical Dept. Fax (+39) 0577 1781690

Registered Office: La Lizza, 7 – 53100 Siena, Italy
e-mail: info@philogen.it – web site: www.philogen.com
Certified e-mail address: amministrazione@pec.philogen.it

Philogen
innovating targeting

Keynote lecture of Prof. Dr. Dario Neri at Festival of Biologics

Siena, Italy (14 October 2019) – Philogen S.p.A, a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that Prof. Dr. Dario Neri, co-founder and Head of the Scientific Advisory Board of Philogen will give a Keynote lecture at the Festival of Biologics in Basel on October 15th. The title of his talk will be: *“Antibody-cytokine fusions: from discovery to Phase III clinical trials”*. Prof. Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich.

For more information please contact:

Philogen

Dr. Christian Lizak

+41 (0) 43 544 88 00

christian.lizak@philogen.com

About Philogen

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com.
